421 related articles for article (PubMed ID: 33220258)
1. PGC1α regulates mitochondrial oxidative phosphorylation involved in cisplatin resistance in ovarian cancer cells via nucleo-mitochondrial transcriptional feedback.
Shen L; Zhou L; Xia M; Lin N; Ma J; Dong D; Sun L
Exp Cell Res; 2021 Jan; 398(1):112369. PubMed ID: 33220258
[TBL] [Abstract][Full Text] [Related]
2. PGC1α promotes cisplatin resistance in human ovarian carcinoma cells through upregulation of mitochondrial biogenesis.
Shen L; Sun B; Sheng J; Yu S; Li Y; Xu H; Su J; Sun L
Int J Oncol; 2018 Jul; 53(1):404-416. PubMed ID: 29749474
[TBL] [Abstract][Full Text] [Related]
3. PGC1α Promotes Cisplatin Resistance in Ovarian Cancer by Regulating the HSP70/HK2/VDAC1 Signaling Pathway.
Li Y; Kang J; Fu J; Luo H; Liu Y; Li Y; Sun L
Int J Mol Sci; 2021 Mar; 22(5):. PubMed ID: 33802591
[TBL] [Abstract][Full Text] [Related]
4. ABT737 reverses cisplatin resistance by targeting glucose metabolism of human ovarian cancer cells.
Xu Y; Gao W; Zhang Y; Wu S; Liu Y; Deng X; Xie L; Yang J; Yu H; Su J; Sun L
Int J Oncol; 2018 Sep; 53(3):1055-1068. PubMed ID: 30015875
[TBL] [Abstract][Full Text] [Related]
5. The Nrf2/PGC1
Deng X; Lin N; Fu J; Xu L; Luo H; Jin Y; Liu Y; Sun L; Su J
Oxid Med Cell Longev; 2020; 2020():4830418. PubMed ID: 33294122
[TBL] [Abstract][Full Text] [Related]
6. Overcoming cisplatin resistance of ovarian cancer cells by targeting HIF-1-regulated cancer metabolism.
Ai Z; Lu Y; Qiu S; Fan Z
Cancer Lett; 2016 Apr; 373(1):36-44. PubMed ID: 26801746
[TBL] [Abstract][Full Text] [Related]
7. Direct impact of cisplatin on mitochondria induces ROS production that dictates cell fate of ovarian cancer cells.
Kleih M; Böpple K; Dong M; Gaißler A; Heine S; Olayioye MA; Aulitzky WE; Essmann F
Cell Death Dis; 2019 Nov; 10(11):851. PubMed ID: 31699970
[TBL] [Abstract][Full Text] [Related]
8. SIRT1/PGC1α-Dependent Increase in Oxidative Phosphorylation Supports Chemotherapy Resistance of Colon Cancer.
Vellinga TT; Borovski T; de Boer VC; Fatrai S; van Schelven S; Trumpi K; Verheem A; Snoeren N; Emmink BL; Koster J; Rinkes IH; Kranenburg O
Clin Cancer Res; 2015 Jun; 21(12):2870-9. PubMed ID: 25779952
[TBL] [Abstract][Full Text] [Related]
9. PGC1α/β Expression Predicts Therapeutic Response to Oxidative Phosphorylation Inhibition in Ovarian Cancer.
Ghilardi C; Moreira-Barbosa C; Brunelli L; Ostano P; Panini N; Lupi M; Anastasia A; Fiordaliso F; Salio M; Formenti L; Russo M; Arrigoni E; Chiaradonna F; Chiorino G; Draetta G; Marszalek JR; Vellano CP; Pastorelli R; Bani M; Decio A; Giavazzi R
Cancer Res; 2022 Apr; 82(7):1423-1434. PubMed ID: 35131872
[TBL] [Abstract][Full Text] [Related]
10. "Metabolic reprogramming" in ovarian cancer cells resistant to cisplatin.
Montopoli M; Bellanda M; Lonardoni F; Ragazzi E; Dorigo P; Froldi G; Mammi S; Caparrotta L
Curr Cancer Drug Targets; 2011 Feb; 11(2):226-35. PubMed ID: 21158717
[TBL] [Abstract][Full Text] [Related]
11. VEGFR2 blockade inhibits glioblastoma cell proliferation by enhancing mitochondrial biogenesis.
Guo M; Zhang J; Han J; Hu Y; Ni H; Yuan J; Sun Y; Liu M; Gao L; Liao W; Ma C; Liu Y; Li S; Li N
J Transl Med; 2024 May; 22(1):419. PubMed ID: 38702818
[TBL] [Abstract][Full Text] [Related]
12. Mitochondrial fission causes cisplatin resistance under hypoxic conditions via ROS in ovarian cancer cells.
Han Y; Kim B; Cho U; Park IS; Kim SI; Dhanasekaran DN; Tsang BK; Song YS
Oncogene; 2019 Nov; 38(45):7089-7105. PubMed ID: 31409904
[TBL] [Abstract][Full Text] [Related]
13. Roflumilast enhances cisplatin-sensitivity and reverses cisplatin-resistance of ovarian cancer cells via cAMP/PKA/CREB-FtMt signalling axis.
Gong S; Chen Y; Meng F; Zhang Y; Li C; Zhang G; Huan W; Wu F
Cell Prolif; 2018 Oct; 51(5):e12474. PubMed ID: 30069985
[TBL] [Abstract][Full Text] [Related]
14. Bcl-2 overexpression reduces cisplatin cytotoxicity by decreasing ER-mitochondrial Ca2+ signaling in SKOV3 cells.
Xu L; Xie Q; Qi L; Wang C; Xu N; Liu W; Yu Y; Li S; Xu Y
Oncol Rep; 2018 Mar; 39(3):985-992. PubMed ID: 29286126
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of mitochondrial translation as a therapeutic strategy for human ovarian cancer to overcome chemoresistance.
Hu B; Guo Y
Biochem Biophys Res Commun; 2019 Feb; 509(2):373-378. PubMed ID: 30591219
[TBL] [Abstract][Full Text] [Related]
16. Diallyl trisulfide alleviates chemotherapy sensitivity of ovarian cancer via the AMPK/SIRT1/PGC1α pathway.
Wang Z; Yan Y; Lou Y; Huang X; Liu L; Weng Z; Cui Y; Wu X; Cai H; Chen X; Ji Y
Cancer Sci; 2023 Feb; 114(2):357-369. PubMed ID: 36309839
[TBL] [Abstract][Full Text] [Related]
17. Tolerance to endoplasmic reticulum stress mediates cisplatin resistance in human ovarian cancer cells by maintaining endoplasmic reticulum and mitochondrial homeostasis.
Xu Y; Wang C; Su J; Xie Q; Ma L; Zeng L; Yu Y; Liu S; Li S; Li Z; Sun L
Oncol Rep; 2015 Dec; 34(6):3051-60. PubMed ID: 26398138
[TBL] [Abstract][Full Text] [Related]
18. Cisplatin resistance in human cervical, ovarian and lung cancer cells.
Chen J; Solomides C; Parekh H; Simpkins F; Simpkins H
Cancer Chemother Pharmacol; 2015 Jun; 75(6):1217-27. PubMed ID: 25894720
[TBL] [Abstract][Full Text] [Related]
19. Combination of Niraparib, Cisplatin and Twist Knockdown in Cisplatin-Resistant Ovarian Cancer Cells Potentially Enhances Synthetic Lethality through ER-Stress Mediated Mitochondrial Apoptosis Pathway.
Bahar E; Kim JY; Kim DC; Kim HS; Yoon H
Int J Mol Sci; 2021 Apr; 22(8):. PubMed ID: 33920140
[TBL] [Abstract][Full Text] [Related]
20. Regulation of apoptosis-inducing factor-mediated, cisplatin-induced apoptosis by Akt.
Yang X; Fraser M; Abedini MR; Bai T; Tsang BK
Br J Cancer; 2008 Feb; 98(4):803-8. PubMed ID: 18283299
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
